GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration
Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 13, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that it signed a Memorandum of Understanding (MOU) with LabConnect...
ENA, Australian Partners Expand Access to Trauma Nursing Education
Association partners with two companies to teach Trauma Nursing Core Course SCHAUMBURG, Ill., Oct. 13, 2026 /PRNewswire/ -- The Emergency Nurses Association has established two new education partners to expand opportunities for nurses in Australia to advance their training in providing care to trauma patients. Advanced Life Support...
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
LUCERNE, Switzerland and NEW DELHI, Oct. 13, 2026 /PRNewswire/ -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting stents (DES) in patients with complex coronary artery disease.Designed to generate comparative evidence, SPARX...
Lunit and Discovery Life Sciences Collaborate to Expand AI-Powered Tissue Analysis for Biopharma Research
Collaboration expands access to Lunit's AI-powered pathology platform by combining it with Discovery Life Sciences' global biospecimen and specialty laboratory capabilities, enabling standardized tissue insights for biomarker research and drug development. SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology,...
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare
GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformation of healthcare from a traditionally reactive model centered on treating illness after it occurs toward a more predictive and proactive approach...
T-MAXIMUM’s B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for the treatment of patients with brain metastases from lung cancer and breast cancer. This is the second...
CLASSYS Appoints Former Bain & Company Partner Jung-hee Bae as Chief Commercial Officer to Accelerate Global Expansion
SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- CLASSYS Inc. (KOSDAQ: 214150), a global medical aesthetics platform company, announced today that it has established the position of Chief Commercial Officer (CCO) and appointed Jung-hee Bae, a former Bain & Company partner, as Vice President, CCO and Head of its newly created Go-to-Market (GTM) Center. Jung-hee Bae, newly...
CLASSYS Appoints Former Bain & Company Partner Jung-hee Bae as Chief Commercial Officer to Accelerate Global Expansion and Growth
- Appoints Vice President Jung-hee Bae to lead the newly established Go-to-Market (GTM) Center, overseeing domestic and international sales and marketing- AI and data-driven marketing and operations expert to spearhead expansion across the Americas, China and Europe while reinforcing the company's leadership in South Korea- Latest executive appointment reinforces CLASSYS's global leadership team following the appointments of CEO...
Three Korean Deep-Tech Firms Seek Singapore Partners in October
The pre-screened companies span smart-city positioning, AI cardiac screening andfunctionalcoatings,withSingaporemeetingsplannedfor26-29October. SINGAPORE, Oct. 12, 2026 /PRNewswire/ -- Three technology companies supported by the Incheon Center for Creative Economy & Innovation (Incheon CCEI) - IDCITI, DeepCardio and JCHI Global - will visit Singapore from 26 to 29 October 2026 to meet potential customers, pilot partners and ecosystem stakeholders across infrastructure,...
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn’s Disease and Ulcerative Colitis at ACG 2026
New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitis Late-breaking analysis shows significantly higher rates of clinical remission and improved endoscopic outcomes with subcutaneous versus intravenous infliximab in patients...
